Moderna Reports $1.9 Billion in 2025 Sales, Exceeds Guidance
Moderna announced 2025 sales of $1.9 billion, surpassing its guidance midpoint while cutting operating expenses and boosting cash reserves. The company aims for 10% revenue growth in 2026 with new vaccine approvals.
Insights:
Moderna Inc. reported 2025 sales of approximately $1.9 billion, marking a significant stabilization in its financial performance after a sharp decline from its 2022 revenue peak of $18.4 billion. This announcement, made during the J.P. Morgan Healthcare Conference in San Francisco, places the company at the upper end of its previously projected $1.6 billion to $2.0 billion forecast range. The achievement comes alongside a strategic reduction in operating expenses by $200 million, setting the new range between $5.0 billion and $5.2 billion.
The company's year-end cash position has also been bolstered to $8.1 billion, exceeding prior forecasts of $6.5 billion to $7.0 billion. This improvement includes a $600 million infusion from a five-year, $1.5 billion loan secured from Ares Management Corporation in November. Moderna's Chief Financial Officer, James Mock james mock, highlighted these financial metrics as indicators of the company's disciplined cost management and strategic financial planning.
